ONESOURCE SPECL PHARMA L ONESOURCE NIFTY_SMALLNSEPHARMA
Company Overview
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Why Investors Should Care
Net profit has compounded at 30.3% per year over the last five years.
Revenue has grown at a 232.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Mar 2026 Revenue of ₹1,421.59 Cr (-1.6% YoY); net profit ₹-73.80 Cr.
- Trailing 12 Months Year-on-year growth — revenue -1.6%, earnings -95.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 232.4%, profit CAGR 30.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 232.38% |
| 1 Year: | -1.61% |
Compounded Profit Growth
| 5 Years: | 30.26% |
| 1 Year: | -95.30% |
Stock Price Performance
| 1 Year: | -17.68% |
| 6 Months: | -6.75% |
| 3 Months: | +8.98% |
| 1 Month: | +1.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 232.4% over 5 years.
- Profit CAGR of 30.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONESOURCE ONESOURCE SPECL PHARMA L NIFTY_SMALLNSEPHARMA | 1,641.50 | -1,007.06 | ₹18,815.07 Cr | 0.00% | 0.45% | -1.27% | 232.38% | 30.26% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.71 Cr | 56.21 Cr | 73.14 Cr | 292.29 Cr | 334.05 Cr | 392.56 Cr | 425.95 Cr | 327.27 Cr | 375.76 Cr | 290.34 Cr | 428.22 Cr |
| Cost of Revenue | - | - | - | - | - | - | 110.91 Cr | 92.92 Cr | 113.49 Cr | 94.37 Cr | 146.26 Cr |
| Gross Profit | - | - | - | - | - | - | 315.05 Cr | 234.35 Cr | 262.27 Cr | 195.97 Cr | 281.95 Cr |
| Operating Expenses | 72.22 Cr | 66.71 Cr | 75.94 Cr | 228.00 Cr | 256.75 Cr | 250.68 Cr | 201.02 Cr | 213.67 Cr | 225.60 Cr | 248.29 Cr | 261.86 Cr |
| Operating Income | -56.94 Cr | -30.03 Cr | -22.33 Cr | -4.06 Cr | 9.02 Cr | 73.11 Cr | 114.02 Cr | 20.68 Cr | 36.67 Cr | -52.31 Cr | 20.09 Cr |
| EBITDA | -38.51 Cr | -10.50 Cr | -2.80 Cr | 64.29 Cr | 77.30 Cr | 141.88 Cr | 185.41 Cr | 90.88 Cr | 109.53 Cr | 14.86 Cr | 94.05 Cr |
| Interest Expense | 24.55 Cr | 26.01 Cr | 20.46 Cr | 42.05 Cr | 45.05 Cr | 45.82 Cr | 33.41 Cr | 27.48 Cr | 33.96 Cr | 38.23 Cr | 22.51 Cr |
| Pretax Income | -113.73 Cr | -130.17 Cr | -40.17 Cr | -46.62 Cr | -37.45 Cr | -66.51 Cr | 83.50 Cr | -4.40 Cr | 5.74 Cr | -93.01 Cr | -29.20 L |
| Tax Provision | -0 | -0 | -0 | 41.07 Cr | -4.63 Cr | -2.35 Cr | -15.69 Cr | -4.21 Cr | -4.74 Cr | -4.31 Cr | -4.89 Cr |
| Net Income | -113.73 Cr | -130.16 Cr | -40.17 Cr | -5.55 Cr | -42.08 Cr | -68.85 Cr | 98.50 Cr | -18.60 L | 10.48 Cr | -88.70 Cr | 4.60 Cr |
| Diluted EPS | - | - | - | - | - | -6.02 | 8.59 | -0.02 | 0.91 | -7.74 | 0.40 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 21.00 Cr | 128.00 Cr | 38.71 Cr | 171.92 Cr | 1,444.85 Cr | 1,421.59 Cr |
| Cost of Revenue | - | - | 20.41 Cr | 70.51 Cr | 435.03 Cr | 444.65 Cr |
| Gross Profit | - | - | 18.30 Cr | 101.41 Cr | 1,009.82 Cr | 976.94 Cr |
| Operating Expenses | 93.00 Cr | 132.00 Cr | 234.19 Cr | 257.94 Cr | 817.19 Cr | 951.81 Cr |
| Operating Income | -105.00 Cr | -57.00 Cr | -215.88 Cr | -156.53 Cr | 192.63 Cr | 25.13 Cr |
| EBITDA | -71.00 Cr | -4.00 Cr | -261.44 Cr | -184.92 Cr | 373.14 Cr | 309.32 Cr |
| Interest Expense | 16.00 Cr | 46.00 Cr | 40.11 Cr | 85.40 Cr | 166.32 Cr | 122.19 Cr |
| Pretax Income | -121.00 Cr | -231.00 Cr | -415.64 Cr | -365.70 Cr | -67.07 Cr | -91.96 Cr |
| Tax Provision | -0 | 0 | 0 | 0 | -49.78 Cr | -18.16 Cr |
| Net Income | -121.00 Cr | -231.00 Cr | -799.83 Cr | -391.17 Cr | -17.97 Cr | -73.80 Cr |
| Diluted EPS | - | - | -69.89 | -34.18 | -1.63 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total Assets | 1,258.00 Cr | 2,442.00 Cr | 2,008.81 Cr | 1,308.61 Cr | 7,550.24 Cr | 8,210.01 Cr |
| Current Assets | - | - | 228.40 Cr | 176.38 Cr | 1,086.18 Cr | 1,425.94 Cr |
| Cash & Equivalents | - | - | 4.97 Cr | 6.47 Cr | 156.48 Cr | 35.68 Cr |
| Inventory | - | - | 133.16 Cr | 11.23 Cr | 158.06 Cr | 438.96 Cr |
| Receivables | - | - | 3.82 Cr | 55.24 Cr | 416.60 Cr | 690.22 Cr |
| Total Liabilities | - | - | 1,223.36 Cr | 912.90 Cr | 1,669.66 Cr | 2,378.72 Cr |
| Current Liabilities | - | - | 865.22 Cr | 630.59 Cr | 1,113.56 Cr | 1,441.97 Cr |
| Long Term Debt | - | - | 334.88 Cr | 271.59 Cr | 219.33 Cr | 563.70 Cr |
| Total Debt | 386.00 Cr | 1,182.00 Cr | 864.22 Cr | 571.17 Cr | 942.44 Cr | 1,503.94 Cr |
| Total Equity | 776.00 Cr | 1,012.00 Cr | 785.45 Cr | 395.71 Cr | 5,880.58 Cr | 5,831.29 Cr |
| Shares Outstanding | - | - | 11.44 Cr | 11.44 Cr | 11.44 Cr | 11.46 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -118.00 Cr | -416.00 Cr | -162.76 Cr | -107.21 Cr | -67.85 Cr | 8.52 Cr |
| Investing Cash Flow | -207.00 Cr | -692.00 Cr | -67.83 Cr | 510.55 Cr | -201.08 Cr | -494.98 Cr |
| Financing Cash Flow | 381.00 Cr | 1,162.00 Cr | 118.32 Cr | -390.54 Cr | 412.01 Cr | 359.44 Cr |
| Capital Expenditure | -207.00 Cr | -655.00 Cr | -43.99 Cr | -63.77 Cr | -128.15 Cr | -569.07 Cr |
| Free Cash Flow | -325.00 Cr | -1,071.00 Cr | -206.76 Cr | -170.98 Cr | -196.00 Cr | -560.55 Cr |
| Net Change in Cash | 56.00 Cr | 54.00 Cr | -112.28 Cr | 12.79 Cr | 143.07 Cr | -127.02 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 47.3% | 59.0% | 69.9% | 68.7% |
| Operating Margin % | -500.0% | -44.5% | -557.6% | -91.0% | 13.3% | 1.8% |
| Net Margin % | -576.2% | -180.5% | -2,066.0% | -227.5% | -1.2% | -5.2% |
| ROE % | -15.6% | -22.8% | -101.8% | -98.9% | -0.3% | -1.3% |
| ROCE % | - | - | -18.9% | -23.1% | 3.0% | 0.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONESOURCE
OneSource Specialty Pharma ties up with Germany’s Formycon for Biosimilar manufacturing - BusinessLine
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxQZWlpci1uVVhjYXB1eXZrOGpwMUpSM05RMnhNZTZUbUt6Zjg1VHdoTlhfNFRMZFRyREhlb3JvLXNjOTI5c0NQOFR1akp4SHNzRnJhajVlMmNuRl9yTWFQbjJOTlREQUhFLVFjT0wyZzh6Z2p1UzRJLVVrNEIzQ2VxUTdsVkFfWXQwV1hZcX…
OneSource Falls 3% on Formycon Manufacturing Deal - Equitypandit
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxON1dFLXFJRUFPRjJnWWZiVXJ6djJtTnp0TllQVENCRnJ6eHE2cERfOWZma3BaZXdHYWNtYzUydXpZemlMUE54ZGU5Vy0xcW8wYWczNjJKZDVDMExVMlFmc1NQb0dqRmZpX2wtUy1VdXRZTFphX2RiM0RMbnl4Qm1DT1UyRTc?oc=5" targ…
Specialty Equipment Distributors Stocks Q1 In Review: Custom Truck One Source (NYSE:CTOS) Vs Peers - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVEltUjNRRjhpMjJKMDEtNmRhTXR4dFp4QW9vOXFxQzV5azdjdjJibjFOTVVVRjZNVmMtcjZFWWZhOUo4cnZxWUxzT1VKYS16S1pTbFNiWURTMW9RZll1c3czY0hpM29vdDNwZldsNkp5QUpySFFmRHZZWkw1LXNDS2xQa3FyOV8zMWhIUF…
Onesource shares fall up to 7% on semaglutide supply delay, guidance cut from key client - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOUGhlQ3ZqNG1zSzhqTmxXbkhsUklIaUxNcXZSRC1ZZUtoeUhPVmFSR0JhQWhwd3JOWS1ra3g3aFVGbE45bFE0ZlduVGZPcE9NUkpTZE9xZ1pEOTNUWXdjNzZvbXNsRGNFeGxvMkt4TzhIdzBidTM4UlRHbGgyVloyUjNYVGNFT3hldE5NWk…
ONESOURCE enters into manufacturing partnership with Formycon AG - Business Standard
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNeDdCOHhTZ0tYVkRtMWlpbHkwQTZ6dkZRakZlaS1DV2IwdjhfUk9LcUk5NzRXakJBUHpQX3MtMnlGbmd1ZHVyNng4Rm9ZckJqdFZpSTVHYklWalNFd2JxTl8wblVKVmcteWI5cm9ackZnVmV2Rk4xRlZjODF5RW5rSVRZaTU0SFM3clk3a2…
ONESOURCE Specialty Pharma and Formycon AG Form Strategic Partnership for Biosimilars Manufacturing - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOQWdJU0V3R3lBUVVPdFVIUzZxZF9yRW5LWXdRVjRqcGJ1YU9VbmMteEdRQTlfcFV6SXZaQnJTV19sVHpvYlR6dmgxbl9qM2hNTDlqWlFpZXpEOW13NEdJTU1UVU5sWXZFVXByVklqT1JUa01ud0xsTmRoeDNVSXUtRkdPV0xrU3VPcUl4ej…
ONESOURCE — Frequently Asked Questions
What is the current share price of ONESOURCE SPECL PHARMA L (ONESOURCE)?
As of 2026-07-15 09:52 IST, ONESOURCE SPECL PHARMA L (ONESOURCE) trades at ₹1,641.50 on NSE. Its 52-week range is ₹1,114.00 to ₹2,002.50.
What is the market capitalisation of ONESOURCE?
ONESOURCE SPECL PHARMA L (ONESOURCE) has a market capitalisation of ₹18,815.07 Cr on NSE.
What is the P/E ratio of ONESOURCE?
ONESOURCE trades at a trailing price-to-earnings (P/E) ratio of -1,007.06. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.30.
What is the return on equity (ROE) of ONESOURCE?
ONESOURCE has a return on equity (ROE) of -1.27%. Its return on capital employed (ROCE) is 0.45%.
Is ONESOURCE a good stock to buy?
This page provides a data-driven analysis of ONESOURCE SPECL PHARMA L (ONESOURCE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.